Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 845-851

  Louie, A ^a   Kaw, P ^a   Liu, W ^a   Jumbe, N ^a   Miller, M H ^a   Drusano, G L ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CULTURE MEDIA; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PROTEIN BINDING; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THIGH;

EID: 0035118552     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.845-851.2001     Document Type: Article

References (33)

1. A new look at the statistical model identification
2. Daptomycin disrupts membrane potential in growing Staphylococcus aureus
3. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
4. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS
5. Effect of 2′,3′-didehydro-3′-desoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies
6. Bactericidal activity of vancomycin, daptomycin, ampicillin, and aminoglycosides against vancomycin-resistant Enterococcus faecium
7. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients
8. Staphylococcus aureus with reduced susceptibility to vancomycin - United States
9. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
10. Protein binding and the antimicrobial effects: Methods for the determination of protein binding
11. Role of pharmacokinetics in the outcome of infections
12. Pharmaeodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas aeruginosa sepsis
13. In vitro and in vivo activity of LY146032, a new cyclic lipopeptide antibiotic
14. An overview of nosocomial infections, including the role of the microbiology laboratory
15. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model
16. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
17. Constant infusion vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro
18. Dissemination in Japanese hospitals of strains of Staphylococcus aureas heterogeneously resistant to vancomycin
19. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
20. In vitro activity of a new cyclic lipopeptide antibiotic. LY146032, against gram-positive clinical bacteria
21. Effect of protein binding of daptomycin on MIC and antibacterial activity
22. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models
23. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci
24. Staphylococcus aureus infections
25. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
26. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin
27. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
28. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats
29. Role for dual individualization with cefmenoxime
30. Daptomycin: A novel agent for Gram-positive infections
31. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
32. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers